Successful treatment with dupilumab of an adult with Netherton syndrome

Clin Exp Dermatol. 2020 Oct;45(7):915-917. doi: 10.1111/ced.14317. Epub 2020 Jul 22.

Authors

T H Andreasen^{1

2}, H G Karstensen³, M Duno³, U Lei¹, C Zachariae¹, J P Thyssen^{1

2}

Affiliations

¹ Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
² CORGIS, Copenhagen Research Group for Inflammatory Skin, Hellerup, Denmark.
³ Department of Clinical Genetics, Rigshospitalet, University Hospital Copenhagen, Hellerup, Denmark.

PMID: 32472705
DOI: 10.1111/ced.14317

No abstract available

Publication types

Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Humans
Male
Netherton Syndrome / drug therapy*
Netherton Syndrome / genetics
Receptors, Interleukin-4 / antagonists & inhibitors*
Serine Peptidase Inhibitor Kazal-Type 5 / genetics
Th2 Cells / physiology

Substances

Antibodies, Monoclonal, Humanized
Receptors, Interleukin-4
SPINK5 protein, human
Serine Peptidase Inhibitor Kazal-Type 5
dupilumab